Urinary L-FABP (uL-FABP) has been extensively studied in preclinical and clinical models and has been suggested as a potential biomarker in a variety of pathological conditions, such as AKI, CKD, diabetic nephropathy, IgA nephropathy, and CI-AKI [114,115]. This evidence concerns the gene FABP1 and IgA glomerulonephritis.